Member Info for Energyshares

This science day should of been live streamed for all PI’s

Poor Avacta

Have they seen a BC patient respond on the trial ????

No mention of STS in RNS pivoting to BC now…

Avacta will highlight the franchise it has developed in breast cancer and how these therapies in this indication will move forward.

£1,®️®️®️,®️®️®️

Working late ….

Https://avacta.com/precision/partnering/

South Korea-based LG Chem has the exclusive rights to develop and commercialise, on a worldwide basis, multiple Affimer® therapeutics intended for treatment of patients in the fields of inflammatory disorders and oncology.

Interesting LG Chem has the exclusive rights to develop and commercialise, on a worldwide basis, multiple Affimer® therapeutics in oncology, I wonder if Third Gen pre|CISION® FAP Affimer® (AffDC) is protected from this agreement…

And Avacta twitter account

Well Christine Coughlin follows him one of his 20 followers

Richard Hughes 8 million shares and a broker Zeus capital waiting for an invitation.

https://x.com/hughesy0707/status/1849746719568757118?s=46

BV

TTB twitter had this slide it says 10 payloads have been FAP enabled.

https://x.com/tom_the_bomb__/status/1846815559280697378?s=46

There is already one Big farmer holding a lot of shares….

Isn’t that right Doggy

This isn’t just a random CEO of a AIM small bio company trying to big up their stock.

She is a world renowned Oncologist making a bold statement and putting her reputation in Oncology on the line.

Let’s see what Rabbit gets pulled out the bag next Wednesday.

“The evolution of preCISION is being unveiled today in Barcelona. We believe the future of cancer therapy means not having to choose between eliminating the disease and safeguarding patient wellness. We believe in hope without compromise. “

#PeptidesCreateHope

#LetsDoThis

#AVCT

Breast,gastric,lung & pancreatic BP will be watching very closely.

That’s billions in revenue

AVA6103: FAP-enabled PDC targeting Topoisomerase I

AVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development. Exatecan has demonstrated clinical activity in breast, gastric, lung and pancreatic cancers; however, it is associated with severe dose-limiting toxicities and a short half-life in patients that led to discontinuation of its monotherapy development. AVA6103 is designed to enable patients to obtain the therapeutic benefit associated with exatecan, while limiting the systemic exposure associated with its poor tolerability.

CC on X

The evolution of preCISION is being unveiled today in Barcelona. We believe the future of cancer therapy means not having to choose between eliminating the disease and safeguarding patient wellness. We believe in hope without compromise.

Tempus TNBC data ASCO 2024

https://www.tempus.com/wp-content/uploads/2024/05/Yuan_TIME-TNBC_2024_ASCO_240506.pdf

https://www.tempus.com/publications/comparison-of-tumor-immune-microenvironments-times-between-primary-and-metastatic-sites-mets-in-triple-negative-breast-cancer-tnbc/?srsltid=AfmBOooT4n07ZUBYumuOqZf1E0_Q_dHKvD88Q1c3QZ4T0sxT4nzYwy7K

Avacta pivot to TNBC in phase 1b

Have they been told to partner Tempus for the data in 1b ?

Big Question which BP is it ?

Take your pick

95% of the top 20 pharma oncology companies partner with Tempus……..

Could these three drugs be in the pipeline ?

Etanercept. (Enbrel)

Arthritis

Ravulizumab. (Ultomiris)

myasthenia gravis ( muscle weakness)

Aflibercept. (Eylea)

Colorectal cancer

All three described on Third Generation pre|CISION® Peptide Drug Conjugate pipeline page with a link to them.

“Attachment of an Fc domain to a drug molecule is a modification used to extend the half-life of a number of approved drugs such as Enbrel®, Eylea® and Ultomiris®.[1] [2]”

https://link.springer.com/article/10.1007/s40259-015-0133-6/tables/5

Triple-negative breast cancer

1st-line treatment for advanced or metastatic TNBC usually consists of chemotherapy alone or in combination with an immunotherapy – options generally associated with response rates between 30 to 50%.2,5,6 Among patients with tumours that do respond to initial treatment, disease progression is common and rapid, often occurring within two years.2,6-8 The average overall survival of patients living with advanced or metastatic TNBC is 12 to 18 months, with only about 14% of patients living five years following diagnosis.9,10

https://www.astrazeneca.com/media-centre/press-releases/2024/update-on-capitello-290-phase-iii-trial.html

AZ big set back with stage 3 trial of TNBC drug ,but they have Enhertu and on a mission to eliminate breast cancer.

AstraZeneca in breast cancer
Driven by a growing understanding of breast cancer biology, AstraZeneca is starting to challenge, and redefine, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need – with the bold ambition to one day eliminate breast cancer as a cause of death.

We could be a excellent partner for them…

These are the Avacta scientists who will be at science day ……

Ruairidh Edwards

Deepa Avisetti

Folake Orafidiya

Doug Sammon

Nico Antrim

Marine Houée

Cindy Tong

Melika Pajouheshpour

Sophie Brown

Hanna B